177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with
breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or
destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2.
177Lu-DOTATATE is a targeted therapy that uses DOTATATE, linked to a radioactive agent called
177Lu. DOTATATE attaches to tumor cells with SSTR2 and delivers 177Lu to kill them. Giving
177Lu-DOTATATE may help decrease the number and size of tumors and the number of circulating
cancer stem cells in patient's blood for the treatment of patients with breast cancer
positive for SSTR2.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Advanced Accelerator Applications Oregon Health and Science University